Abstract
We report the case of a patient with B-cell prolymphocytic leukemia who was successfully treated with the novel humanized monoclonal antibody obinutuzumab. This patient was previously treated with the combination of rituximab and bendamustine and had recurrent infusion reactions. Her treatment with rituximab and bendamustine was discontinued when she developed disease progression after 3 cycles of therapy. She was then treated with obinutuzumab 1000 mg on day 1 of every cycle and chlorambucil 0.5 mg/kg on days 1 and 15 every 28 days to which she had greater tolerability. After 4 cycles of treatment, she had resolution of her clinical symptoms, massive splenomegaly, and normalization of her white blood cell count.
Highlights
B-cell prolymphocytic leukemia (B-PLL) is a rare mature B-cell neoplasm that typically occurs in the elderly population
We report the case of an elderly female with a diagnosis of B-PLL who displayed an excellent clinical response to chemo-immunotherapy with a combination of obinutuzumab and chlorambucil after failing initial treatment with bendamustine and rituximab
There is a considerable overlap in the clinicopathologic presentation of this disorder and other mature B-cell leukemias/lymphomas, such as chronic lymphocytic leukemia (CLL), hairy cell leukemia variant, and splenic marginal zone lymphoma
Summary
B-cell prolymphocytic leukemia (B-PLL) is a rare mature B-cell neoplasm that typically occurs in the elderly population. Conventional chemotherapy has been used in the past including combination regimens such as cyclophosphamide, doxorubicin, Oncovin, and prednisolone (CHOP), which has yielded only partial responses. These responses are not durable with relapses usually occurring within 12 months. Another option for selected patients is allogeneic stem cell transplant. Allogeneic stem cell transplant, is best reserved for the few, younger and fit patients with this disease It is associated with a high risk of morbidity and mortality.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Investigative Medicine High Impact Case Reports
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
